Results 101 to 110 of about 6,725 (159)

Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials. [PDF]

BMC Cancer
Wei C, Liu S, Hu J, Cao B, Liu B.
europepmc   +1 more source

Niraparib Regimen [PDF]

, 2020
openaire   +1 more source

Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery. [PDF]

Cancers (Basel)
Miedziarek C, Caputa P, Bochyński H, Zaborowski MP, Nowak-Markwitz E.   +4 more
europepmc   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review. [PDF]

Gynecol Oncol Rep
Arab W, Kassis NE, Khoury C, Mansour H, Chahine G, Atallah D.   +5 more
europepmc   +1 more source

The Future of all-Comers Trials in the Era of Precision Oncology. [PDF]

Clin Pharmacol Ther
Williams JA, Jain N, MacNish Porter C, Cui B, Gutjahr TS.   +4 more
europepmc   +1 more source

Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases. [PDF]

Front Oncol
Vascotto IA, Catalano M, Venturini J, Calandrelli C, Mancini S, Pratesi L, Izzi M, Mela MM, Rossi V, Francini E, Pillozzi S, Antonuzzo L, Roviello G.   +12 more
europepmc   +1 more source

Maintenance therapy in gynecologic malignancies: Current and future state. [PDF]

Cancer
Widick PC, Wright AA, Liu JF.
europepmc   +1 more source

Case Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas. [PDF]

Front Oncol
Zeal JL, Woodcock MG, Chen KY, Stein JN.
europepmc   +1 more source

Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX). [PDF]

Front Oncol
Pathak P, Jo E, Hilsenbeck S, Anderson ML, Echeverria A, Sharma S, Sunde J, Hall T, Costales A, Hoppenot C, Ludwig M.   +10 more
europepmc   +1 more source